Study shows promise in treating cow’s milk allergy in children

A new clinical trial has shown promising results in treating cow’s milk allergy (CMA) in children. Specifically, the study found that 12 months of daily epicutaneous immunotherapy with a 300 μg dose of Viaskin milk led to significant treatment response in children aged 2 to 11 years with IgE-mediated CMA.

In addition, the trial reported low rates of treatment-related adverse events, indicating that Viaskin milk could potentially serve as a safe and effective treatment option for this common childhood allergy.

The phase 1/2 double-blind, placebo-controlled study involved children aged 2 to 17 years with confirmed IgE-mediated CMA. The research comprised 2 parts: part A focused on evaluating the safety of different doses of Viaskin milk, whereas part B delved into both efficacy and safety over a 12-month treatment period.

Of the 308 screened participants, 198 met eligibility criteria and were randomized. The study found that 12 months of daily epicutaneous immunotherapy with a 300 μg dose of Viaskin milk led to significant treatment response in children aged 2 to 11 years. Specifically, 49% of participants in this group showed a positive response compared to 30.2% in the placebo group.

The trial also reported low rates of treatment-related adverse events, with most being mild or moderate application-site reactions. Only 1 participant in the 500-μg Viaskin milk dose group experienced treatment-related anaphylaxis.

Further investigation is warranted to fully explore its potential and ensure its safety and efficacy as a therapeutic intervention for this common childhood allergy.

Reference
Petroni D, Bégin P, Bird JA, Brown-Whitehorn T, et al. Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy: A Randomized Clinical Trial. JAMA Pediatr. 2024 Feb 26. doi: 10.1001/jamapediatrics.2023.6630. Epub ahead of print. PMID: 38407859.